Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDO.

ABSTRACT: In November 2022, the findings of the Avoiding Late Diagnosis of Ovarian cancer (ALDO) study were published. Subsequent media coverage suggested that investigators had found a safe alternative to risk-reducing bilateral salpingoophorectomy (rrBSO) in patients with pathogenic BRCA1 and BRCA2 germline mutations who chose to decline or defer risk-reducing surgery. Unfortunately, this media coverage was largely misleading. Specifically, in the ALDO trial, 4 of 6 patients found to have ovarian cancer by the ALDO screening methodology were diagnosed with advanced-stage disease. The primary endpoint of the ALDO study was the rate of complete surgical cytoreduction, rather than stage at diagnosis or overall survival, which is an inappropriate surrogate for benefit in a population at

SUBMITTER: Manning-Geist BL 

PROVIDER: S-EPMC10020112 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature